细胞毒性T细胞
背景(考古学)
癌症研究
免疫系统
细胞溶解
生物
细胞生物学
表型
自然杀伤细胞
过继性细胞移植
体内
免疫学
离体
淋巴因子激活杀伤细胞
化学
细胞毒性
肿瘤浸润淋巴细胞
细胞
T细胞
免疫疗法
白细胞介素12
细胞培养
细胞分化
免疫分型
抗原
细胞疗法
体外
作者
Nina B. Horowitz,Imran A. Mohammad,June Ho Shin,John W. Hickey,Peter Chockley,Gail Snyder,Chen Chen,Keene Lee,Krishna Sharma,Quan Tran,Anahita Nejatfard,Sainiteesh Maddineni,Vasu Divi,Catherine A. Blish,Garry P. Nolan,Jennifer A. Foltz,John B. Sunwoo
标识
DOI:10.1126/scitranslmed.adw5567
摘要
Human tissue-resident natural killer (NK) cells (trNK cells), broadly defined by markers of tissue residency, such as CD49a [ integrin α 1 ( ITGA1 )] and CD103 [ integrin α E ( ITGAE )], are increasingly recognized for their immunoregulatory role in host control of infection, malignancy, and autoimmunity. Although the importance of transforming growth factor–β in trNK cell differentiation has been demonstrated, the context in which the differentiation of CD49a + CD103 + trNK cells occurs can result in either an immunosuppressive phenotype (e.g., decidual NK cells) or a highly cytotoxic one (e.g., some tumor trNK subsets). To understand this dichotomy better, we used a multiomic approach to molecularly characterize these cells. We identified a cytotoxic trNK (ctrNK) cell population, characterized by the expression of CD39. These ctrNK cells exhibited superior cytolytic activity against tumor target cells, enhanced capacity to infiltrate into solid tumor microenvironments, and augmented ability to control solid tumor growth in vivo compared with conventionally activated peripheral NK cells. This heightened cytolytic and infiltrative functionality of ctrNK cells appeared to be conferred, in part, by the expression of CD103 and by avidity for tumor targets. Because adoptive immune cell therapy of solid tumor malignancies has been challenged by the inefficiency of ex vivo expanded immune cells to infiltrate immunosuppressive solid tumor microenvironments, our observations that ctrNK cells can be differentiated and expanded ex vivo present a potential platform for adoptive cell therapy of solid tumor malignancies.
科研通智能强力驱动
Strongly Powered by AbleSci AI